Regulus Therapeutics (RGLS)
(Real Time Quote from BATS)
$1.64 USD
-0.01 (-0.61%)
Updated Aug 30, 2024 02:04 PM ET
4-Sell of 5 4
F Value D Growth F Momentum F VGM
Brokerage Reports
Regulus Therapeutics Inc. [RGLS]
Reports for Purchase
Showing records 1 - 20 ( 274 total )
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Exploratory Analyses Reinforce Data in ADPKD; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
ADPKD Trial Reports Positive Cohort 3 Data; Reiterate Buy; Raising PT to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
1Q24 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Phase 1b ADPKD Trial Advances to Cohort 4; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
2023 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Dose Response and TKV Reduction in ADPKD Study Cohort 2; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Third Cohort of the Phase 1b ADPKD Study Completes Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Genomic Medicine Deep Dive-Redrawing Frontiers at the Coding Level
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
3Q23 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Patient Dosing Commences in Cohort 3 of Phase 1b MAD Study; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Phase 1b MAD Study Reports Positive Cohort 1 Topline Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Phase 1b MAD Study Completes Cohort 2 Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
2Q23 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Phase 1b ADPKD Trial Starts Patient Dosing in Second Cohort; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Preclinical Program For ALS Advances to Lead Compound Evaluation; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
1Q23 Financial Results; Competitive Landscape Improves; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Phase 1b Study First Cohort Completes Enrollment; Financing Closed; Reiterate Buy; Lowering PT to $9
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Phase 1b MAD Study of RGLS8429 Starts Patient Dosing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
2Q22 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Partner?s Alport Syndrome Program Terminated; Reit. Buy; Reverse Stock Split Leads to $20 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R